AbbVie - ABBV Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $177.43
Forecasted Upside: 4.65%
Number of Analysts: 13
Breakdown:
0 Sell Ratings
3 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$169.54 As of 04/23/2024 01:00 AM ET

▲ +1.65 (0.98%)

1 month | 3 months | 12 months

Get New AbbVie Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ABBV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABBV

^$177.43

▲ +4.65% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $177.43, with a high forecast of $196.00 and a low forecast of $150.00. The average price target represents a 4.65% upside from the last price of $169.54.

Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in AbbVie. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

11/1/2022

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/30/2023

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/30/2023

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/29/2023

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/27/2023

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/25/2024

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/25/2024

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/24/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/27/2024	Barclays	Boost Target	Overweight ➝ Overweight	$185.00 ➝ $195.00	Low
3/22/2024	Guggenheim	Boost Target	Buy ➝ Buy	$188.00 ➝ $190.00	Low
2/6/2024	Truist Financial	Boost Target	Buy ➝ Buy	$180.00 ➝ $195.00	Low
2/5/2024	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$187.00 ➝ $195.00	Low
2/5/2024	Barclays	Boost Target	Overweight ➝ Overweight	$175.00 ➝ $185.00	Low
2/5/2024	Raymond James	Boost Target	Outperform ➝ Outperform	$181.00 ➝ $189.00	Low
1/29/2024	William Blair	Upgrade	Market Perform ➝ Outperform		Low
1/23/2024	Barclays	Boost Target	Overweight ➝ Overweight	$170.00 ➝ $175.00	Low
12/18/2023	HSBC	Downgrade	Buy ➝ Hold	$167.00 ➝ $156.00	Low
12/11/2023	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$173.00	Low
12/1/2023	Raymond James	Boost Target	Outperform ➝ Outperform	$177.00 ➝ $181.00	Low
11/9/2023	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$150.00	Low
10/30/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$193.00 ➝ $196.00	Low
10/30/2023	Barclays	Upgrade	Equal Weight ➝ Overweight	$160.00 ➝ $170.00	Low
10/20/2023	UBS Group	Lower Target	Neutral	$157.00 ➝ $150.00	Low
10/11/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$189.00 ➝ $193.00	Low
9/28/2023	Raymond James	Initiated Coverage	Outperform	$177.00	Low
7/28/2023	Piper Sandler Companies	Boost Target	Overweight	$163.00 ➝ $170.00	Low
7/28/2023	Piper Sandler	Boost Target	Overweight	$163.00 ➝ $170.00	Low
7/25/2023	William Blair	Initiated Coverage	Market Perform		Low
7/14/2023	HSBC	Initiated Coverage	Buy	$167.00	Low
7/12/2023	Credit Suisse Group	Lower Target		$170.00 ➝ $160.00	Low
4/28/2023	Guggenheim	Lower Target		$172.00 ➝ $171.00	Low
4/28/2023	Wells Fargo & Company	Lower Target		$200.00 ➝ $195.00	Low
4/12/2023	Barclays	Boost Target		$155.00 ➝ $160.00	Low
4/10/2023	Morgan Stanley	Boost Target	Overweight	$178.00 ➝ $181.00	Low
4/5/2023	Argus	Downgrade	Buy ➝ Hold		Low
2/28/2023	Guggenheim	Initiated Coverage	Buy	$172.00	Low
2/22/2023	Wolfe Research	Downgrade	Outperform ➝ Peer Perform		Low
2/10/2023	Atlantic Securities	Lower Target	Neutral	$157.00 ➝ $154.00	Low
2/10/2023	Morgan Stanley	Lower Target	Overweight	$182.00 ➝ $178.00	Low
2/10/2023	Piper Sandler Companies	Boost Target	Overweight	$157.00 ➝ $163.00	Low
2/10/2023	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$135.00 ➝ $153.00	Low
2/10/2023	SVB Securities	Upgrade	Underperform ➝ Market Perform	$135.00 ➝ $153.00	Low
2/9/2023	Piper Sandler	Boost Target	Overweight	$157.00 ➝ $163.00	Low
2/6/2023	BMO Capital Markets	Lower Target	Outperform	$169.00 ➝ $167.00	Low
1/17/2023	Piper Sandler	Boost Target	Overweight	$155.00 ➝ $157.00	Low
1/5/2023	Truist Financial	Boost Target		$160.00 ➝ $180.00	Low
12/6/2022	Morgan Stanley	Boost Target	Overweight	$178.00 ➝ $182.00	Low
11/17/2022	Credit Suisse Group	Initiated Coverage	Outperform	$170.00	Low
11/8/2022	Societe Generale	Downgrade	Buy ➝ Hold	$155.00 ➝ $140.00	Low
10/31/2022	Atlantic Securities	Lower Target	Neutral	$162.00 ➝ $157.00	Low
10/31/2022	Morgan Stanley	Lower Target	Overweight	$185.00 ➝ $178.00	Low
10/31/2022	Barclays	Lower Target	Equal Weight	$160.00 ➝ $155.00	Low
10/31/2022	BMO Capital Markets	Lower Target	Outperform	$170.00 ➝ $169.00	Low
10/11/2022	Morgan Stanley	Lower Target	Overweight	$188.00 ➝ $185.00	Low
9/30/2022	SVB Leerink	Lower Target	Underperform	$140.00 ➝ $135.00	Low
8/24/2022	Argus	Lower Target	Buy	$165.00 ➝ $155.00	Low
8/9/2022	Barclays	Lower Target		$160.00	N/A
8/1/2022	Morgan Stanley	Lower Target	Overweight	$191.00 ➝ $188.00	Low
8/1/2022	UBS Group	Lower Target	Neutral	$154.00 ➝ $146.00	Low
8/1/2022	Atlantic Securities	Lower Target	Overweight ➝ Neutral	$178.00 ➝ $162.00	Low
7/29/2022	Piper Sandler	Lower Target		$160.00 ➝ $155.00	Low
7/27/2022	UBS Group	Boost Target	Outperform	$154.00	Low
7/8/2022	Morgan Stanley	Boost Target	Overweight	$188.00 ➝ $191.00	N/A
5/23/2022	SVB Leerink	Initiated Coverage	Underperform	$140.00	High
5/6/2022	Daiwa Capital Markets	Downgrade	Outperform ➝ Neutral	$150.00	Low
5/2/2022	Wells Fargo & Company	Boost Target		$165.00 ➝ $200.00	Medium
4/25/2022	BMO Capital Markets	Boost Target	Outperform	$161.00 ➝ $174.00	Medium
4/12/2022	The Goldman Sachs Group	Boost Target	Neutral	$122.00 ➝ $140.00	High
4/12/2022	Barclays	Boost Target	Equal Weight	$150.00 ➝ $174.00	High
4/6/2022	Morgan Stanley	Boost Target	Overweight	$142.00 ➝ $192.00	Medium
3/1/2022	Citigroup	Boost Target		$155.00 ➝ $170.00	Low
2/28/2022	UBS Group	Downgrade	Buy ➝ Neutral	$129.00 ➝ $147.00	Low
2/4/2022	Mizuho	Boost Target	Buy	$154.00 ➝ $166.00	Low
2/3/2022	JPMorgan Chase & Co.	Boost Target		$165.00 ➝ $180.00	Low
2/3/2022	Bank of America	Boost Target	Neutral	$135.00 ➝ $138.00	Medium
2/3/2022	The Goldman Sachs Group	Boost Target	Neutral	$117.00 ➝ $122.00	Medium
2/3/2022	BMO Capital Markets	Boost Target	Outperform	$153.00 ➝ $154.00	Medium
2/3/2022	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$133.00 ➝ $150.00	High
1/27/2022	Citigroup	Boost Target		$125.00 ➝ $155.00	Medium
1/24/2022	Morgan Stanley	Boost Target	Overweight	$124.00 ➝ $142.00	Medium
1/20/2022	Barclays	Boost Target	Equal Weight	$118.00 ➝ $133.00	High
1/18/2022	Cowen	Boost Target		$130.00 ➝ $150.00	High
1/13/2022	Redburn Partners	Initiated Coverage	Buy		High
1/12/2022	BMO Capital Markets	Boost Target	Outperform	$134.00 ➝ $153.00	Low
1/5/2022	Mizuho	Boost Target	Buy	$132.00 ➝ $154.00	Medium
1/3/2022	Piper Sandler	Boost Target		$129.00 ➝ $160.00	Low
12/17/2021	The Goldman Sachs Group	Initiated Coverage	Neutral	$113.00	High
12/8/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$165.00	High
12/7/2021	BMO Capital Markets	Reiterated Rating	Buy	$134.00	Low
12/7/2021	SVB Leerink	Reiterated Rating	Buy		Low
11/24/2021	Truist Financial	Boost Target	Buy	$118.00 ➝ $135.00	Low
11/23/2021	Societe Generale	Upgrade	Hold ➝ Buy		High
11/1/2021	Barclays	Boost Target	Equal Weight	$112.00 ➝ $118.00	Low
11/1/2021	SVB Leerink	Lower Target	Outperform	$142.00 ➝ $135.00	Low
11/1/2021	Morgan Stanley	Boost Target	Overweight	$116.00 ➝ $124.00	Low
10/29/2021	Piper Sandler	Boost Target	Overweight	$124.00 ➝ $129.00	Low
9/2/2021	SVB Leerink	Lower Target	Outperform	$148.00 ➝ $142.00	Medium
8/23/2021	Cowen	Boost Target	Outperform	$120.00 ➝ $130.00	Low
8/20/2021	Morgan Stanley	Reiterated Rating	Buy	$116.00	Low
8/20/2021	SVB Leerink	Boost Target	Outperform	$145.00 ➝ $148.00	Low
8/5/2021	Argus	Boost Target	Buy ➝ Buy	$130.00 ➝ $140.00	Low
8/2/2021	SVB Leerink	Boost Target	Outperform	$144.00 ➝ $145.00	Medium
8/2/2021	Mizuho	Boost Target	Buy	$128.00 ➝ $131.00	Medium
8/2/2021	Barclays	Boost Target	Equal Weight	$105.00 ➝ $112.00	Medium
7/27/2021	Truist Financial	Initiated Coverage	Buy	$117.00	Low
7/2/2021	Daiwa Capital Markets	Initiated Coverage	Outperform		Low
5/3/2021	BMO Capital Markets	Boost Target	Outperform	$127.00 ➝ $129.00	High
5/3/2021	Mizuho	Boost Target	Buy	$126.00 ➝ $128.00	High
4/30/2021	Piper Sandler	Boost Target	Overweight	$120.00 ➝ $124.00	Low
4/7/2021	Royal Bank of Canada	Initiated Coverage		$135.00	Low
3/30/2021	SVB Leerink	Boost Target	Outperform	$140.00 ➝ $144.00	Low
2/4/2021	SVB Leerink	Boost Target	In-Line ➝ Outperform	$128.00 ➝ $140.00	Low
2/4/2021	Royal Bank of Canada	Boost Target	Outperform	$129.00 ➝ $135.00	Low
2/4/2021	Mizuho	Boost Target	Buy	$117.00 ➝ $126.00	Low
1/28/2021	Morgan Stanley	Lower Target	Overweight	$120.00 ➝ $116.00	Medium
12/16/2020	SVB Leerink	Boost Target	Outperform	$119.00 ➝ $128.00	Medium
12/15/2020	Mizuho	Boost Target		$111.00 ➝ $117.00	Medium
11/30/2020	Morgan Stanley	Boost Target	Positive ➝ Overweight	$108.00 ➝ $120.00	Low
11/18/2020	BMO Capital Markets	Initiated Coverage	Outperform	$123.00 ➝ $123.00	Medium
11/10/2020	Sanford C. Bernstein	Initiated Coverage	Outperform	$120.00	High
11/2/2020	SVB Leerink	Lower Target	Outperform	$122.00 ➝ $119.00	High
10/23/2020	Truist Financial	Initiated Coverage	Buy	$110.00	Low
10/20/2020	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell		High
10/16/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$115.00 ➝ $120.00	Low
9/29/2020	Berenberg Bank	Initiated Coverage	Hold	$98.00	Low
9/27/2020	Mizuho	Reiterated Rating	Buy	$111.00	Low
9/2/2020	Citigroup	Boost Target	Buy	$98.00 ➝ $105.00	Medium
8/20/2020	Morgan Stanley	Boost Target	Overweight	$95.00 ➝ $108.00	Medium
8/3/2020	Mizuho	Boost Target	Buy	$110.00 ➝ $111.00	Low
8/3/2020	Royal Bank of Canada	Boost Target	Outperform	$125.00 ➝ $127.00	Low
6/29/2020	Mizuho	Boost Target	Top Pick ➝ Buy	$101.00 ➝ $110.00	Low
6/25/2020	Royal Bank of Canada	Boost Target	Outperform	$102.00 ➝ $125.00	Medium
6/23/2020	Atlantic Securities	Upgrade	Neutral ➝ Overweight	$115.00	Medium
6/18/2020	Royal Bank of Canada	Reiterated Rating	Buy	$102.00	Low
6/17/2020	UBS Group	Boost Target		$96.00 ➝ $109.00	Low
6/10/2020	Evercore ISI	Initiated Coverage	Buy	$111.00	High
6/10/2020	Piper Sandler	Boost Target		$97.00 ➝ $110.00	High
6/9/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform		Low
6/2/2020	Argus	Upgrade	Hold ➝ Buy	$91.40 ➝ $115.00	Low
5/28/2020	Royal Bank of Canada	Reiterated Rating	Buy	$102.00	Low
5/18/2020	Bank of America	Initiated Coverage	Neutral	$95.00	Low
5/12/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$105.00	Medium
5/11/2020	Morgan Stanley	Reiterated Rating	Overweight	$95.00	High
5/11/2020	SVB Leerink	Boost Target	Outperform	$107.00 ➝ $122.00	High
5/4/2020	SVB Leerink	Boost Target	Outperform	$103.00 ➝ $107.00	Low
5/1/2020	Mizuho	Reiterated Rating	Buy	$100.00	Medium
4/20/2020	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$79.00 ➝ $93.00	Low
4/13/2020	UBS Group	Lower Target	Buy	$106.00 ➝ $96.00	Low
4/12/2020	Royal Bank of Canada	Reiterated Rating	Hold	$79.00	Low
3/23/2020	Societe Generale	Downgrade	Buy ➝ Hold		High
2/27/2020	Barclays	Initiated Coverage	Equal Weight	$97.00 ➝ $97.00	High
2/18/2020	Cowen	Boost Target	Outperform	$98.00 ➝ $105.00	Low
2/10/2020	Mizuho	Boost Target		$96.00 ➝ $104.00	High
2/7/2020	Piper Sandler	Boost Target	Overweight	$95.00 ➝ $97.00	Low
2/5/2020	Mizuho	Initiated Coverage	Buy	$96.00 ➝ $96.00	Low
1/23/2020	Royal Bank of Canada	Reiterated Rating	Hold	$86.00	High
1/6/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$86.00	Low
1/3/2020	Bank of America	Downgrade	Buy ➝ Neutral		Low
12/26/2019	Cowen	Boost Target	Outperform	$90.00 ➝ $98.00	Low
11/20/2019	Citigroup	Boost Target	Buy	$90.00 ➝ $98.00	Medium
11/19/2019	UBS Group	Boost Target	Buy	$79.00 ➝ $96.00	High
11/1/2019	Piper Sandler Companies	Boost Target		$81.00 ➝ $90.00	High
9/26/2019	Citigroup	Upgrade	Neutral ➝ Buy	$87.00 ➝ $90.00	Medium
9/24/2019	Cowen	Set Target	Buy	$90.00	Low
9/12/2019	UBS Group	Upgrade	Neutral ➝ Buy	$85.00 ➝ $79.00	Low
9/4/2019	Piper Sandler Companies	Boost Target	Overweight	$80.00 ➝ $81.00	Medium
8/20/2019	Piper Sandler Companies	Upgrade	Neutral ➝ Overweight	$80.00	High
7/26/2019	Piper Sandler Companies	Set Target	Hold	$80.00	N/A
7/2/2019	SVB Leerink	Upgrade	Buy		Low
6/27/2019	Wolfe Research	Upgrade	Underperform ➝ Peer Perform		Medium
6/26/2019	Citigroup	Reiterated Rating	Hold		Medium
6/26/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$88.00	High
5/28/2019	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$84.00	High
4/28/2019	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$71.00 ➝ $79.00	Low
4/26/2019	Credit Suisse Group	Set Target	Sell	$78.00	Low

(Data available from 4/24/2019 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

37 very positive mentions
41 positive mentions
4 negative mentions
3 very negative mentions

Mentions as of

9/27/2023

41 very positive mentions
30 positive mentions
8 negative mentions
5 very negative mentions

Mentions as of

10/27/2023

31 very positive mentions
47 positive mentions
5 negative mentions
4 very negative mentions

Mentions as of

11/26/2023

50 very positive mentions
33 positive mentions
12 negative mentions
3 very negative mentions

Mentions as of

12/26/2023

53 very positive mentions
50 positive mentions
3 negative mentions
3 very negative mentions

Mentions as of

1/25/2024

67 very positive mentions
70 positive mentions
6 negative mentions
1 very negative mentions

Mentions as of

2/24/2024

54 very positive mentions
43 positive mentions
1 negative mentions
4 very negative mentions

Mentions as of

3/25/2024

60 very positive mentions
68 positive mentions
9 negative mentions
3 very negative mentions

Mentions as of

4/24/2024

Current Sentiment

Recent Stories by Sentiment

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Today's Range

Now: $169.54

$168.29

$170.37

50 Day Range

MA: $175.26

$161.67

$182.10

52 Week Range

Now: $169.54

$130.96

$182.89

Volume

4,084,061 shs

Average Volume

5,615,517 shs

Market Capitalization

$300.20 billion

P/E Ratio

62.10

Dividend Yield

3.73%

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of AbbVie?: The following sell-side analysts have issued research reports on AbbVie in the last year: Barclays PLC, BMO Capital Markets, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, HSBC Holdings plc, Morgan Stanley, Piper Sandler, Piper Sandler Companies, Raymond James, StockNews.com, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., UBS Group AG, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for ABBV.
What is the current price target for AbbVie?: 14 Wall Street analysts have set twelve-month price targets for AbbVie in the last year. Their average twelve-month price target is $177.43, suggesting a possible upside of 4.7%. Morgan Stanley has the highest price target set, predicting ABBV will reach $196.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $150.00 for AbbVie in the next year.
View the latest price targets for ABBV.
What is the current consensus analyst rating for AbbVie?: AbbVie currently has 3 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ABBV.
What other companies compete with AbbVie?: Other companies that are similar to AbbVie include Merck & Co., Inc., Johnson & Johnson, Pfizer, Bristol-Myers Squibb and IQVIA. Learn More about companies similar to AbbVie.
How do I contact AbbVie's investor relations team?: AbbVie's physical mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company's listed phone number is (847) 932-7900. The official website for AbbVie is www.abbvie.com. Learn More about contacing AbbVie investor relations.

AbbVie - ABBV Stock Price Target and Predictions

Analyst Price Target for ABBV

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.68 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of AbbVie?

What is the current price target for AbbVie?

What is the current consensus analyst rating for AbbVie?

What other companies compete with AbbVie?

How do I contact AbbVie's investor relations team?